Lucentis Meets Phase III Endpoint in DME

Genentech’s Phase III study evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

@font-face { font-family: “Cambria”; }@font-face { font-family: “Optima”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times New Roman”; }div.Section1 { page: Section1; } @font-face { font-family: “Cambria”; }@font-face { font-family: “Optima”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters